Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of 5-naphthylidene-2,4-thiazolidinedione derivatives as selective HDAC8 inhibitors and evaluation of their cytotoxic effects in leukemic cell lines
Kalpana Tilekar, Neha Upadhyay, Niklas Jänsch, et al.
Bioorganic Chemistry (2019) Vol. 95, pp. 103522-103522
Closed Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

An overview on applications of SwissADME web tool in the design and development of anticancer, antitubercular and antimicrobial agents: A medicinal chemist's perspective
Bulti Bakchi, Ambati Dileep Krishna, Ekambarapu Sreecharan, et al.
Journal of Molecular Structure (2022) Vol. 1259, pp. 132712-132712
Closed Access | Times Cited: 150
Pathological Role of HDAC8: Cancer and Beyond
Ji Yoon Kim, Hayoung Cho, Jung Yoo, et al.
Cells (2022) Vol. 11, Iss. 19, pp. 3161-3161
Open Access | Times Cited: 49
Contribution of Knoevenagel Condensation Products toward the Development of Anticancer Agents: An Updated Review
Ramya Tokala, Darshana Bora, Nagula Shankaraiah
ChemMedChem (2022) Vol. 17, Iss. 8
Closed Access | Times Cited: 35
A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors
Anna Fontana, Ilaria Cursaro, Gabriele Carullo, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 17, pp. 10014-10014
Open Access | Times Cited: 30
Discovery of novel N-substituted thiazolidinediones (TZDs) as HDAC8 inhibitors: in-silico studies, synthesis, and biological evaluation
Neha Upadhyay, Kalpana Tilekar, Niklas Jänsch, et al.
Bioorganic Chemistry (2020) Vol. 100, pp. 103934-103934
Open Access | Times Cited: 43
Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)
Yuxiang Luo, Huilin Li
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 22, pp. 8828-8828
Open Access | Times Cited: 40
Synthesis, antitumor, and apoptosis-inducing activities of novel 5-arylidenethiazolidine-2,4-dione derivatives: Histone deacetylases inhibitory activity and molecular docking study
Abdelrahman Hamdi, Walaa M. El-Husseiny, Dina I. A. Othman, et al.
European Journal of Medicinal Chemistry (2022) Vol. 244, pp. 114827-114827
Closed Access | Times Cited: 23
Significance of Five-Membered Heterocycles in Human Histone Deacetylase Inhibitors
Anton Frühauf, Martin Behringer, Franz‐Josef Meyer‐Almes
Molecules (2023) Vol. 28, Iss. 15, pp. 5686-5686
Open Access | Times Cited: 16
Non-Hydroxamate Zinc-Binding Groups as Warheads for Histone Deacetylases
Anton Frühauf, Franz‐Josef Meyer‐Almes
Molecules (2021) Vol. 26, Iss. 17, pp. 5151-5151
Open Access | Times Cited: 31
The medicinal perspective of 2,4‐thiazolidinediones based ligands as antimicrobial, antitumor and antidiabetic agents: A review
Kumari Kajal, Gurpreet Singh, Tathagata Pradhan, et al.
Archiv der Pharmazie (2022) Vol. 355, Iss. 9
Closed Access | Times Cited: 20
Thiazolidinedione derivatives: emerging role in cancer therapy
Ganesh Latambale, Kapil Juvale
Molecular Diversity (2025)
Closed Access
Permuted 2,4-thiazolidinedione (TZD) analogs as GLUT inhibitors and their in-vitro evaluation in leukemic cells
Kalpana Tilekar, Neha Upadhyay, Markus Schweipert, et al.
European Journal of Pharmaceutical Sciences (2020) Vol. 154, pp. 105512-105512
Open Access | Times Cited: 32
Structure guided design and synthesis of furyl thiazolidinedione derivatives as inhibitors of GLUT 1 and GLUT 4, and evaluation of their anti-leukemic potential
Kalpana Tilekar, Neha Upadhyay, Jessica D. Hess, et al.
European Journal of Medicinal Chemistry (2020) Vol. 202, pp. 112603-112603
Open Access | Times Cited: 28
Synthesis and Biological Evaluation of Pyrazoline and Pyrrolidine‐2,5‐dione Hybrids as Potential Antitumor Agents
Kalpana Tilekar, Neha Upadhyay, Franz‐Josef Meyer‐Almes, et al.
ChemMedChem (2020) Vol. 15, Iss. 19, pp. 1813-1825
Closed Access | Times Cited: 28
Thiazolidinedione “Magic Bullets” Simultaneously Targeting PPARγ and HDACs: Design, Synthesis, and Investigations of their In Vitro and In Vivo Antitumor Effects
Kalpana Tilekar, Jessica D. Hess, Neha Upadhyay, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 10, pp. 6949-6971
Closed Access | Times Cited: 26
Design, synthesis, and molecular docking studies of thiazolidinediones as PPAR‐γ agonists and thymidylate synthase inhibitors
Syed Nazreen
Archiv der Pharmazie (2021) Vol. 354, Iss. 9
Closed Access | Times Cited: 21
Synthesis, molecular modelling and pharmacological evaluation of novel indole-thiazolidinedione based hybrid analogues as potential pancreatic lipase inhibitors
Ginson George, Prashant S. Auti, Pracheta Sengupta, et al.
Journal of Biomolecular Structure and Dynamics (2023), pp. 1-20
Open Access | Times Cited: 9
Multi-target weapons: diaryl-pyrazoline thiazolidinediones simultaneously targeting VEGFR-2 and HDAC cancer hallmarks
Neha Upadhyay, Kalpana Tilekar, Sabreena Safuan, et al.
RSC Medicinal Chemistry (2021) Vol. 12, Iss. 9, pp. 1540-1554
Open Access | Times Cited: 15
Double-edged Swords: Diaryl pyrazoline thiazolidinediones synchronously targeting cancer epigenetics and angiogenesis
Neha Upadhyay, Kalpana Tilekar, Sabreena Safuan, et al.
Bioorganic Chemistry (2021) Vol. 116, pp. 105350-105350
Closed Access | Times Cited: 15
HDAC8 As an Emerging Target in Drug Discovery With Special Emphasis on Medicinal Chemistry
S. Rajaraman, Ranjani Balakrishnan, Dhruv Deshmukh, et al.
Future Medicinal Chemistry (2023) Vol. 15, Iss. 10, pp. 885-908
Closed Access | Times Cited: 6
A Review on Molecular Docking on HDAC Isoforms: Novel Tool for Designing Selective Inhibitors
Aliki Drakontaeidi, Eleni Pontiki
Pharmaceuticals (2023) Vol. 16, Iss. 12, pp. 1639-1639
Open Access | Times Cited: 4
Medicinal Perspective of 2,4‐Thiazolidinediones Derivatives: An Insight into Recent Advancements
Sneha Gupta, Sumeet Jha, Supriya Rani, et al.
ChemistryOpen (2024)
Open Access | Times Cited: 1
Mechanistic Insights into Binding of Ligands with Thiazolidinedione Warhead to Human Histone Deacetylase 4
Markus Schweipert, Niklas Jänsch, Neha Upadhyay, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 10, pp. 1032-1032
Open Access | Times Cited: 10
Histone deacetylase 8 in focus: Decoding structural prerequisites for innovative epigenetic intervention beyond hydroxamates
Samima Khatun, Indrasis Dasgupta, Sudip Sen, et al.
International Journal of Biological Macromolecules (2024) Vol. 284, pp. 138119-138119
Closed Access | Times Cited: 1
Repurposing of DrugBank molecules as dual non-hydroxamate HDAC8 and HDAC2 inhibitors by pharmacophore modeling, molecular docking, and molecular dynamics studies
Kakali Sarkar, Sudhan Debnath, Rajat Ghosh, et al.
Journal of Biomolecular Structure and Dynamics (2024), pp. 1-23
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top